J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's device revenue growth is still hindered by declining sales of the Cypher sirolimus-eluting coronary stent, the company reported during its first-quarter earnings call April 17
You may also be interested in...
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years
Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
New Data Is Likely To Add Fuel To The Drug-Eluting-Stent Debate
New trial data presented at the American College of Cardiology annual meeting could be another obstacle to drug-eluting-stent manufacturers' efforts to reverse a year-long sales slump